Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats.
Isoniazid, rifampicin and pyrazinamide during short-course chemotherapy for tuberculosis can result in liver injury. The coexistence of tuberculosis and diabetes is common in patients who receive inadequate treatment. The risk of hepatotoxicity from many toxicants is increased in diabetic rats. Silymarin provides protection against liver injury caused by many hepatotoxicants, including antitubercular drugs (ATDs). In the wake of increased severity of ATD-induced hepatotoxicity in diabetes we report here the results of a study on the influence of diabetes on silymarin hepatoprotection in rats. Rats with diabetes induced via intraperitoneally injected streptozotocin (50 mg/kg), nondiabetic rats and insulin-treated diabetic rats received isoniazid (7.5 mg/kg/day), rifampicin (10 mg/kg/day) and pyrazinamide (35 mg/kg/day) orally (p.o.) with or without silymarin (100 mg/kg/day p.o.) treatment for 45 days. Compared to nondiabetic rats, liver function tests and histological changes of liver revealed exaggerated liver injury in diabetic rats caused by ATDs which was evident by 5- to 8-fold increases in serum levels of marker enzymes (aspartate and alanine aminotransferase, alkaline phosphatase and gamma-glutamyltranspeptidase) and 1- to 2-fold increases in bilirubin accompanied by a 2-fold decrease in total serum proteins, intense fatty and inflammatory infiltrations, necrosis and fibrosis. Coadministration of silymarin provided protection against ATD hepatotoxicity in all animals. However, insulin-treated diabetic animals showed greater silymarin-induced hepatoprotection against ATD-induced liver injury, which was characterized by near normal levels of marker enzymes, an increase in total proteins and normal hepatic structure. These results thus indicate that diabetes exaggerates ATD-induced liver injury and attenuates silymarin-induced hepatoprotection. However, insulin treatment for diabetes offers greater silymarin-induced hepatoprotection against ATD-induced liver injury.
Srivastava
R K
RK
Department of Pharmacology, Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India. rajnikant0629@yahoo.co.in
Sharma
S
S
Verma
S
S
Arora
B
B
Lal
H
H
D000818:Animals; D000995:Antitubercular Agents / Q000009:adverse effects*; D001663:Bilirubin / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000503:physiopathology; D005260:Female; D007538:Isoniazid / Q000009:adverse effects; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008107:Liver Diseases / Q000517:prevention & control*; D008111:Liver Function Tests; D008297:Male; D020011:Protective Agents / Q000494:pharmacology; D011718:Pyrazinamide / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D012293:Rifampin / Q000009:adverse effects; D012838:Silymarin / Q000494:pharmacology*; D013311:Streptozocin
D000995:Antitubercular Agents; D020011:Protective Agents; D012838:Silymarin; D011718:Pyrazinamide; D013311:Streptozocin; D001663:Bilirubin; D007538:Isoniazid; D012293:Rifampin